Zimmer Biomet Holdings stock
ZBHNYSEZimmer Biomet Holdings, Inc., HealthcareISIN US98956P1021
68Score 68 out of 100, Neutral
Price and trend
85 / 100
Price history
+16% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 5.1% below its 52-week high. Largest decline in 20 years: 65% (April 2007 to March 2009).
Chart figures for advanced users
- SMA 50$95.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$92.44
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$79.58
- The lowest closing price of the last twelve months.
- Resistance$110.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Zimmer Biomet Holdings, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $19.79B, is number 12 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $8.23B (up 7.2% year on year) and earnings of $705.2M (down 22%).
- For fiscal 2026, analysts expect on average revenue of $8.61B (up 4.7%) and adjusted earnings per share of $8.55 (up 4.3%).
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 178 of 714 in Healthcare, median 53.
- The P/E is 26.1 (Medical (Devices) median 29, own median of recent years 26.2).
- Our model puts fair value at $121.56, with the price 12% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 216% of earnings over the last 12 months.Fundamentals 75
- Reliable dividendNo dividend cut for 14 years.Capital allocation 57
- Earnings per share growingUp 17.4% a year since 2021.Growth 69
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $93.51 and expensive above $173.66 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $126.75 (cash-flow model) and $116.37 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $111.84, at 8.5% it would be $135.46.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 62%, operating 17%, net 9%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 9 Feb 2027in 89 days
- Last reported
- 4 Nov 2026EPS reported $1.90 (expected $1.88)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $8.55+0.3%
- Revenue
- $8.61B+0.2%
- Earnings per share
- $8.98−0.8%
- Revenue
- $8.9B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.4%2026 organic revenue growth guidance raised to 2.25% to 3.25% (before: 1% to 3%) and adjusted EPS to $8.47 to $8.59 (before: $8.40 to $8.55).
“With a strong first half, the transition to a dedicated and specialized U.S. sales channel progressing as planned, continued new product momentum and healthy underlying markets, we are raising our full year organic constant currency revenue guidance to 2.25% to 3.25% from the previous range of 1% to 3%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.24M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Zimmer Biomet Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
- Koninklijke PhilipsPHIA.AS $29.51B56
- Terumo4543.T $23.31B76
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
- Smith & NephewSNN $12.99B67
- PenumbraPEN $12.68B59
ETFs that hold Zimmer Biomet Holdings
Held by 112 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 2.74% | 0.49% | €368.7M |
| iShares Ageing Population UCITS ETF2B77 | 0.58% | 0.40% | €807M |
| Amundi MSCI Robotics & AI UCITS ETF AccGOAI | 0.45% | 0.40% | €1.14B |
Show 5 more
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.42% | 0.75% | €140.24M |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.40% | 0.20% | €268.74M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.31% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.31% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.30% | 0.15% | €592.11M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.